Industry
Tianjin ConjuStar Biologics Co., Ltd.
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
2 recruiting
Enrollment Performance
Analytics
Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT07080619Phase 2Not Yet Recruiting
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
Role: lead
NCT06220838Phase 1Recruiting
Study SC-101 in Subjects With Advanced Malignancies
Role: lead
NCT06710158Phase 1Recruiting
Study of SC-102 in Patients With Advanced Solid Tumors
Role: lead
All 3 trials loaded